Your email has been successfully added to our mailing list.

×
0 0 0 0 0.000166389351081512 0.0482529118136438 0.08153078202995 0.0565723793677203
Stock impact report

Elite Pharmaceuticals receives FDA approval on its NDA for ADHD treatment [Seeking Alpha]

Elite Pharmaceuticals, Inc. (ELTP) 
NASDAQ:AMEX Investor Relations: ir.elitepharma.com
Company Research Source: Seeking Alpha
version of Vyvanse with strengths of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg capsules. The product is indicated for the treatment of Attention Deficit Hyperactivity Disorder. Stock is up 5% premarket. Source: Press Release More on Elite Pharmaceuticals Elite Pharmaceuticals, Inc. (ELTP) Q2 2025 Earnings Conference Call Transcript Financial information for Elite Pharmaceuticals Recommended For You Comments More Trending News Show less Read more
Impact Snapshot
Event Time:
ELTP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for ELTP alerts
Opt-in for
ELTP alerts

from News Quantified
Opt-in for
ELTP alerts

from News Quantified